搴旈┈纾婅€佸笀閭€璇凤紝University of Texas at El Paso鐨勬湵鑰€鐞冿紙Yaoqiu Zhu锛夊崥澹皢鏉ユ垜闄㈠仛涓€鍦哄鏈姤鍛婏紝娆㈣繋鎰熷叴瓒ｇ殑鑰佸笀鍚屽銆佸挨鍏舵槸甯屾湜缁х画鍦ㄥ浗澶栬鍗氭垨鍗氬悗鐨勭爺绌剁敓鍙傚姞鎶ュ憡锛屾姤鍛婁細鍚庢湵鑰€鐞冨崥澹皢璁炬湁鎷涚敓鍜ㄨ鐜妭銆�
鎶ュ憡棰樼洰锛歍he Chemistry of a Cardiovascular Medicine (Plavix): Exploring the Human Body 鈥淩eaction Factory鈥�, Unraveling the Clinical Puzzle, and Discovering the Next Generation Medication
鎶ュ憡浜�锛歒aoqiu Zhu, Ph.D.锛孉ssistant Professor锛孌epartment of Chemistry, University of Texas at El Paso
鎶ュ憡鏃堕棿锛�2011骞�11鏈�23鏃ワ紙鍛ㄤ竴锛変笂鍗�10锛�00鐐�
鎶ュ憡鍦扮偣锛氬疄楠�18妤�420浼氳瀹�
Abstract: The focus of the seminar is the broad definition of medicinal chemistry: the chemical sciences of a medicine in human (patient) body. The seminar presents speaker鈥檚 recent independent discoveries on clopidogrel (Plavix), an antithrombotic drug that has shown high inter-subject variability and irresponsiveness in its 18 years clinical use. Comprehensive biochemical studies have revealed a dual role of the human body on clopidogrel and unraveled its long-overdue clinical puzzle. Based on these understandings, a series of medicinal chemistry strategies have been formulated for overcoming the therapeutic drawbacks of this blockbuster drug. These demonstrate that rational chemistry studies of 鈥渕edicine in human body鈥� can accelerate the discovery of the next generation therapies and therapeutics, and novel biomedical and pharmaceutical research methodologies can be developed to facilitate this.
Relevant Publication (* sole corresponding author)
3. Yaoqiu Zhu*, Jiang Zhou, and Bo Jiao 鈥淐lopidogrel Analogues as a New Generation of Antiplatelet Agents鈥� ACS Med. Chem. Lett. 2013, 4, 349-352.
2. Yaoqiu Zhu* and Jiang Zhou 鈥淚n Vitro Biotransformation Studies of 2-Oxo-clopidogrel: Multiple Thiolactone Ring Opening Pathways Further Attenuate Prodrug Activation鈥� Chem. Res. Toxicol. 2013, 26, 179-190.
1. Yaoqiu Zhu* and Jiang Zhou 鈥淚dentification of the Significant Involvement and Mechanistic Role of CYP3A4/5 in Clopidogrel Bioactivation鈥� ACS Med. Chem. Lett. 2012, 3, 844-849.
Speaker鈥檚 Bio
Dr. Zhu obtained his B.S. of Chemistry in 2001 at Peking University in Beijing, China. Under the supervision of Prof. Richard B. Silverman (inventor of Pfizer鈥檚 blockbuster drug Lyrica) in the Department of Chemistry at Northwestern University, he conducted doctoral research on enzyme chemistry and got his Ph.D. in 2006. With a strong interest in drug discovery, he then joined Abbott Laboratories as a senior research scientist. Dr. Zhu conducted 鈥渟tructure and drug-like property relationship鈥� studies for over 20 internal R&D projects including a program that has eventually yielded the recently approved HCV drug Viekira Pak (AbbVie). After worked at Abbott for over two years, Dr. Zhu resigned and founded his own contract research company, MetabQuest. He independently built a drug metabolism and medicinal chemistry lab in Beijing, China. He and his team have worked with pharmaceutical companies and research institutes on various medicinal chemistry projects and preclinical studies. In addition, Dr. Zhu鈥檚 lab has participated in several translational drug discovery research collaborations involving Harvard Medical School, University of Pittsburgh, Northwestern University, China Pharmaceutical University, Cambria Biosciences, etc. To pursue the long-term goal of becoming a medicinal chemistry professor, since 2012, Dr. Zhu has closed his company and devoted his lab to academic research projects, including 鈥淚nvestigation of the clinical drawbacks of Plavix (BMS & Sanofi) and discovery of novel antiplatelet agents鈥�. Recently he accepted a tenure-track assistant professor position at Department of Chemistry in University of Texas at El Paso. Dr. Zhu鈥檚 academic research focuses on novel methodologies for biomedical research and cancer drug discovery.